1. Signaling Pathways
  2. Neuronal Signaling
  3. Monoamine Oxidase

Monoamine Oxidase

MAO

Monoamine oxidases (MAO) are a family of enzymes that catalyze the oxidation of monoamines. They are found bound to the outer membrane of mitochondria in most cell types in the body. They belong to the protein family of flavin-containing amine oxidoreductases. Monoamine oxidases catalyze the oxidative deamination of monoamines. Oxygen is used to remove an amine group from a molecule, resulting in the corresponding aldehyde and ammonia. Monoamine oxidases contain the covalently bound cofactor FAD and are, thus, classified as flavoproteins. Because of the vital role that MAOs play in the inactivation of neurotransmitters, MAO dysfunction is thought to be responsible for a number of psychiatric and neurological disorders. MAO-A inhibitors act as antidepressant and antianxiety agents, whereas MAO-B inhibitors are used alone or in combination to treat Alzheimer’sand Parkinson’s diseases.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-149242
    MAO-B-IN-20
    Inhibitor
    MAO-B-IN-20 (Compound C14) is a potent MAO-B inhibitor with an IC50 of 0.037 μM. MAO-B-IN-20 displays good metabolic stability and brain-blood barrier permeability. MAO-B-IN-20 can be used for the research of Parkinson's disease.
    MAO-B-IN-20
  • HY-149528
    MAO-B-IN-24
    Inhibitor
    MAO-B-IN-24 (compound 11h) is a selective, reversible, competitive inhibitor of MAO-B (IC50: 1.60 μM). MAO-B-IN-24 also inhibited MAO-A (22.42 μM); at 10 μM concentration, it also reduced AChE and BChE activities to 54.58% and 88.43%.
    MAO-B-IN-24
  • HY-14198R
    Selegiline (Standard)
    Inhibitor
    Selegiline (Standard) is the analytical standard of Selegiline. This product is intended for research and analytical applications. Selegiline (Deprenyl) is a potent, selective and irreversible inhibitor of MAO-B, with an IC50 of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC50=23 μM). Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder.
    Selegiline (Standard)
  • HY-14605BS
    Rasagiline-13C3 mesylate racemic
    Inhibitor
    Rasagiline-13C3 (mesylate racemic) is a 13C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1]. Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Rasagiline-<sup>13</sup>C<sub>3</sub> mesylate racemic
  • HY-156348
    MAO-B-IN-26
    Inhibitor
    MAO-B-IN-26 (Compound IC9) is a MAO-B and acetylcholinesterase inhibitor. MAO-B-IN-26 protects SH?SY5Y cells against Aβ induced cytotoxicity, morphological changes, ROS generation and membrane damage. MAO-B-IN-26 also inhibits Aβ induced autophagy and apoptosis. MAO-B-IN-26 can be used as a neuroprotective agent against Alzheimer’s disease.
    MAO-B-IN-26
  • HY-Y0882S1
    Hydroxylamine-d3 hydrochloride
    Hydroxylamine-d3 (hydrochloride) is the deuterium labeled Hydroxyamine hydrochloride[1]. Hydroxyamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis[2].
    Hydroxylamine-d<sub>3</sub> hydrochloride
  • HY-170487
    MAO-B-IN-38
    Inhibitor
    MAO-B-IN-38 (Compound 6b) is a reversible and competitive MAO-B inhibitor, with IC50 values of 0.03 and 21.46 µM for MAO-B and MAO-A, respectively. MAO-B-IN-38 can be used for the research of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases.
    MAO-B-IN-38
  • HY-146315
    AChE/BChE-IN-6
    Inhibitor
    AChE/BChE-IN-6 (compound 22) is a potent dual AChE/BChE inhibitor with IC50 values of 0.809 µM, 2.248 µM and > 100 µM for hBChE, hAChE and hMAO-B, respectively. AChE/BChE-IN-6 penetrates the blood-brain barrier (BBB). AChE/BChE-IN-6 can be used for Alzheimer’s disease (AD) research.
    AChE/BChE-IN-6
  • HY-N1636
    1-Methyl-2-nonyl-4(1H)-quinolone
    Inhibitor
    1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective MAO-B (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC50 of 12.1 μM.
    1-Methyl-2-nonyl-4(1H)-quinolone
  • HY-168138
    MAO-B-IN-34
    Inhibitor
    MAO-B-IN-34 (compund 3d) is a monoamine oxidase MAO-B inhibitor.
    MAO-B-IN-34
  • HY-151210
    MAO-B-IN-17
    Inhibitor ≥99.0%
    MAO-B-IN-17 is a selective monoamine oxidase B (MAO-B) inhibitor with the IC50 value of 5.08 μM. MAO-B-IN-17 can be used in Parkinson’s disease research.
    MAO-B-IN-17
  • HY-163474
    MAO-B-IN-32
    Inhibitor
    MAO-B-IN-32 is an inhibitor of MAO-B (IC50 = 16 nM).MAO-B-IN-32 increases dopamine concentration in the brain by inhibiting MAO-B activity.
    MAO-B-IN-32
  • HY-151562
    AChE/BuChE/MAO-B-IN-1
    Inhibitor
    AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC50s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ1 and σ2 receptors with Ki values of 42.8 nM (human σ1 receptor) and 191 nM (rat σ2 receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research.
    AChE/BuChE/MAO-B-IN-1
  • HY-127109A
    Tisolagiline methylsulfate
    Inhibitor
    Tisolagiline methylsulfate is a reversible MAO-B inhibitor used in Parkinson's disease research.
    Tisolagiline methylsulfate
  • HY-135265
    Moclobemide N-Oxide
    Inhibitor
    Moclobemide N-Oxide (Ro 12-5637) is N-oxide metabolite of Moclobemide. Moclobemide N-Oxide retains certain MAO-A (monoamine oxidase) inhibitory activity, but is generally present in low concentrations. Moclobemide N-Oxide can be detected by UV absorption at 240 nm.
    Moclobemide N-Oxide
  • HY-144790
    AChE-IN-12
    Inhibitor
    AChE-IN-12 is a potent and blood-brain barrier (BBB) penetrant acetylcholinesterase (AChE) with IC50s of 0.41 μM and 1.88 μM for rat AChE and electric eel AChE. AChE-IN-12 is also a good antioxidant (ORAC = 3.3 eq), selective metal chelator and huMAO-B inhibitor (IC50 = 8.8 μM). AChE-IN-12 has remarkable inhibition of self- and Cu2+-induced Aβ1-42 aggregation, as well as exhibits a good neuroprotective effect. AChE-IN-12 can be used for researching Alzheimer’s disease.
    AChE-IN-12
  • HY-151094
    FTEAA
    Inhibitor
    FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC50s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research.
    FTEAA
  • HY-152114
    AChE/BChE/MAO-B-IN-4
    Inhibitor
    AChE/BChE/MAO-B-IN-4, an indan-1-one derivative, is a potent MAO-B inhibitor with an IC50 of 0.0393 μM for human MAO-B. AChE/BChE/MAO-B-IN-4 is a potent AChE and BChE enzyme inhibitor, with IC50s of 0.0458 μM and 0.075 μM for human AChE and BChE enzyme, respectively. AChE/BChE/MAO-B-IN-4 shows significant antioxidant activity and prevent β-amyloid plaque aggregation. AChE/BChE/MAO-B-IN-4 has the potential for Alzheimer's disease (AD) research.
    AChE/BChE/MAO-B-IN-4
  • HY-155580
    MAO A/HSP90-IN-2
    Inhibitor
    MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape[1].
    MAO A/HSP90-IN-2
  • HY-111016
    LJP 1586
    Inhibitor
    LJP 1586 is an amine-based inhibitor of semicarbazide-sensitive amine oxidase (SSAO) activity. LJP 1586 is an orally active, potent and selective inhibitor of rodent and human SSAO activity, with IC50 values between 4 and 43 nM.
    LJP 1586
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.